{
  "id": 4635416,
  "title": "Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation",
  "url": "https://urgent.news/2026/08/31/axsome-therapeutics-initiates-summit-phase-3-trial-of-axs-05-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-31T11:05:02.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/axsome-therapeutics-initiates-summit-phase-3-trial-of-axs-05-in-smoking-cessation"
  },
  "original_language": "en",
  "account": null,
  "summary": "NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}